FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a crystalline semihydrate form of HA (S)-N-((S)-1-cyclohexyl-2-{(S)-2-[4-(4-fluorobenzoyl)thiazol-2-yl]pyrrolidin-1-yl}-2-oxoethyl)-2-methylamino-propionamide described by formula chiral (I)
and being an apoptosis protein inhibitor, which protects cancer cells from apoptosis-caused death. The crystalline semihydrate form of HA compound (I) is characterised by an X-ray powder diffraction pattern containing three or more 2θ values specified in a group consisting of 8.3±0.2, 9.5±0.2, 13.5±0.2, 17.3±0.2, 18.5±0.2 and 18.9±0.2 at room temperature. The crystalline semihydrate form of HA compound (I) is also characterised by an X-ray powder diffraction pattern, a heat pattern of differential scanning calorimetry and a thermographic analysis pattern.
EFFECT: non-hygroscopic and stable polymorphic form of (S)-N-((S)-1-cyclohexyl-2-{(S)-2-[4-(4-fluorobenzoyl)thiazol-2-yl]pyrrolidin-1-yl}-2-oxoethyl)-2-methylaminopropionamide.
5 cl, 18 dwg, 10 tbl, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SOLID ORAL FORMULATIONS AND CRYSTALLINE FORMS OF APOPTOSIS PROTEIN INHIBITOR | 2010 |
|
RU2671196C1 |
| COMBINATION OF IAP AND FLT3 INHIBITORS | 2007 |
|
RU2456983C2 |
| STABLE FORMULATIONS OF IMANITIB | 2008 |
|
RU2470641C2 |
| SALTS AND CRYSTALLINE FORMS | 2014 |
|
RU2654855C2 |
| CRYSTALLINE FORMS OF FINGOLIMOD HYDROCHLORIDE | 2009 |
|
RU2549899C2 |
| NOVEL CRYSTALLINE FORMS OF SODIUM SALT OF (4-{4-[5-(6-TRIFLUOROMETHYL-PYRIDIN-3-YLAMINO)PYRIDIN-2-YL]PHENYL}CYCLOHEXYL) ACETIC ACID | 2011 |
|
RU2612556C2 |
| CRYSTALLINE FORMS OF THE TLR7/TLR8 INHIBITOR | 2019 |
|
RU2792005C2 |
| COMPOSITIONS CONTAINING BAZEDOXIFENE ACETATE | 2006 |
|
RU2417084C2 |
| CRYSTALLINE FORMS OF LTA4H INHIBITOR | 2019 |
|
RU2808992C2 |
| SALT OF PYRROLIDIN-3-YL-ACETIC ACID DERIVATIVE AND ITS CRYSTALS | 2014 |
|
RU2640047C2 |
